A $3B+ unmet clinical need. Zero FDA-approved treatments. One first-mover. RTST Pharma is advancing HPR-01™ through an accelerated FDA regulatory pathway — redefining the science of prevention and recovery.
Annual global economic burden from alcohol-induced impairment
Of occasional drinkers report veisalgia symptoms following overconsumption
FDA-approved or clinically validated pharmaceutical treatments available
The global response to veisalgia has been relegated to folklore, anecdotal remedies, and unregulated supplement formulations making unproven claims. No pharmaceutical company has advanced a fixed-dose combination therapy through rigorous clinical validation — until RTST Pharma.
HPR-01™ is a proprietary fixed-dose combination (FDC) of two well-characterized generic pharmaceutical agents with established safety profiles, formulated to deliver simultaneous gastric protection and neurological recovery through complementary, clinically rationalized mechanisms of action.
Component 1 suppresses pro-inflammatory cytokine cascade and reduces gastric mucosal inflammation — directly resolving the gastrointestinal symptom burden associated with acute alcohol metabolism.
Component 2 restores neurotransmitter homeostasis and accelerates acetaldehyde detoxification via enhanced metabolic clearance — targeting the neurological impairment at its biochemical source.
No NDA holder exists for this therapeutic indication. HPR-01™ is positioned to establish category leadership in a pharmaceutical segment with zero incumbent competitors.
HPR-01™ leverages well-established generic agents with extensive existing safety data, enabling a rational, expedited FDA review strategy and a materially de-risked development timeline.
Both active components carry decades of published clinical literature. HPR-01™ combines their established pharmacodynamics into a novel fixed-dose formulation with a documented efficacy rationale.
The veisalgia therapeutics market is growing at ~15% CAGR with demonstrated consumer willingness-to-pay and existing OTC distribution channels primed for pharmaceutical-grade disruption.
RTST Pharma was founded by Dr. Tshibangu, a clinician-scientist whose work at the intersection of lifestyle medicine and pharmaceutical innovation has driven the development of HPR-01™ from mechanistic insight to a structured FDA regulatory strategy. Based in Pittsford, New York, RTST Pharma combines the precision of evidence-based medicine with a deep commitment to addressing unmet clinical needs of modern patients worldwide.
Our mission is to empower individuals to take control of their health through safe, transformative therapeutics that meet the highest standards of pharmaceutical science — accessible, validated, and built for the real world.
For accredited investors and institutional partners. Deck delivered under NDA upon request.
RTST Pharma is advancing HPR-01™ through pre-IND preparations, with clinical development milestones planned on an accelerated timeline leveraging the existing pharmacological data of its component agents.
Millions experience veisalgia symptoms annually, yet rigorous clinical research has historically overlooked this therapeutic indication — until now.
Read moreModern health challenges are increasingly rooted in lifestyle patterns. RTST Pharma exists precisely where pharmaceutical precision meets real-world clinical need.
Read moreHealthcare must evolve beyond reactive treatment. RTST Pharma's pipeline begins with HPR-01™ and extends the frontier of prevention science globally.
Read moreReach our team in Pittsford, New York to discuss investment, partnership, or clinical collaboration opportunities.
